Publication Type : Conference Proceedings
Publisher : Blood
Source : Blood. 2017 Dec 8;130:5398.
Url : https://www.sciencedirect.com/science/article/pii/S0006497119859141
Campus : Kochi
School : School of Medicine
Year : 2017
Abstract : Background: The standard of care for patients with newly diagnosed multiple myeloma is induction chemotherapy using novel agents followed by autologous stem cell transplantation, if eligible. In resource limited countries, generic drugs have allowed wider access to novel agents. There is limited data on the outcome of patients treated with induction therapy with generic novel agents. Hence we evaluated the clinical outcomes of patients with newly diagnosed multiple myeloma initiated on a common induction therapy consisting of Cyclophosphamide - Bortezomib - Dexamethasone (CyBorD) using generic Bortezomib at two centres in India.
Cite this Research Publication : Sidharthan N, Sivadas A, Devasia AJ, Kulkarni UP, Sudevan R, Pavithran K, Prabhu R, Ganapathy R, Philip A, Jose W, Unni M. Response and Survival in Newly Diagnosed Multiple Myeloma Patients Treated with Cybord Regimen Using Generic Bortezomib—Data from Two Centres from India. Blood. 2017 Dec 8;130:5398.